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Abstract
Background: The treatment of high-risk neuroblastoma patients consists of multimodal induction therapy to
achieve remission followed by consolidation therapy to prevent relapses. However, the type of consolidation
therapy is still discussed controversial. We applied metronomic chemotherapy in the prospective NB90 trial and
monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of
the patient cohort.
Methods: A total of 334 stage 4 neuroblastoma patients one year or older were included. All patients successfully
completed the induction therapy. In the NB90 trial, 99 patients received at least one cycle of the oral maintenance
chemotherapy (NB90 MT, 12 alternating cycles of oral melphalan/etoposide and vincristine/cyclophosphamide).
In the NB97 trial, 166 patients commenced the MAB ch14.18 consolidation therapy (six cycles over 12 months).
Patients who received no maintenance therapy according to the NB90 protocol or by refusal in NB97 (n = 69)
served as controls.
Results: The median observation time was 11.11 years. The nine-year event-free survival rates were 41 ± 4%, 31 ±
5%, and 32 ± 6% for MAB ch14.18, NB90 MT, and no consolidation, respectively (p = 0.098). In contrast to earlier
reports, MAB ch14.18 treatment improved the long-term outcome compared to no additional therapy (p = 0.038).
The overall survival was better in the MAB ch14.18-treated group (9-y-OS 46 ± 4%) compared to NB90 MT (34 ±
5%, p = 0.026) and to no consolidation (35 ± 6%, p = 0.019). Multivariable Cox regression analysis revealed
ch14.18 consolidation to improve outcome compared to no consolidation, however, no difference between
NB90 MT and MAB ch14.18-treated patients was found.
Conclusions: Follow-up analysis of the patient cohort indicated that immunotherapy with MAB ch14.18 may
prevent late relapses. Finally, metronomic oral maintenance chemotherapy also appeared effective.
Background
The prognosis of high-risk neuroblastoma patients has
improved over the last decades. However, even after
high intensive treatment only a few patients become
long-term survivors [1-3]. Most high-risk patients
develop relapse after initial response to induction treat-
ment. Prevention of these relapses by additional con-
ventional chemotherapy is limited due to cumulative
toxicity. Thus, additional treatments to chemotherapy,
surgery, and radiotherapy have to be sought. Metro-
nomic low dose chemotherapy was considered to have
the potential to prevent relapses with acceptable low
toxicity. Therefore, an oral chemotherapy with cyclo-
phosphamide, etoposide and melphalan was introduced
in trial NB90. Monoclonal antibodies (MAB) directed
against GD2 have offered another promising avenue of
treatment [4-10]. Therefore, the chimeric human/mouse
antibody ch14.18 was applied as consolidation treatment
in pilot patients of the trial NB90 and all high-risk
patients in the NB97. Early analysis of MAB ch14.18
consolidation in high-risk neuroblastoma patients did
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[11,12]. Here, we present the long-term outcome of the
cohort.
Methods
A total of 334 patients of the Cooperative German Neu-
roblastoma Trials NB90 and NB97 were included in this
analysis when they met the following inclusion criteria:
(1) stage 4 neuroblastoma diagnosed according to the
INSS criteria [13], (2) age at diagnosis one year or older,
(3) diagnosis between September 01, 1989 and January
01, 2002, (4) treatment according to the NB90/NB97
neuroblastoma trials, (5) no event (relapse, progression,
death, secondary malignant disease) during induction
chemotherapy, (6) no combination of NB90 mainte-
nance treatment and ch14.18 antibody, (7) no additional
treatment with 13 cis-retinoic acid, and (8) informed
parents’ consent for treatment and the collection of
data.
NB90 induction chemotherapy consisted of four N1
chemotherapy cycles (cisplatin, etoposide, vindesine)
and four N2 cycles (vincristine, dacarbacine, ifosfamide,
doxorubicine) [1]. Myeloablative chemotherapy with
autologuous stem cell transplantation (ASCT) was an
option for patients in complete or very good partial
remission. Patients not treated with ASCT received
maintenance therapy consisting of alternating cycles D1
(oral melphalan 8 mg/m²/d days 1-5 and oral etoposide
100 mg/m²/d days 1-5) and D2 (intravenous vincristine
1.5 mg/m² day 1 and oral cyclophosphamide 150 mg/
m²/d days 1-7) each month for one year [1]. In NB97,
the NB90 induction chemotherapy was detoxified by
r e d u c t i o no ft h ee t o p o s i d ed o s eb y2 0% ,t h ed o x o r u b i -
cine infusion time from 48 to 4 hours on two consecu-
tive days, and the total number of chemotherapy cycles
from 8 to 6. Induction was followed by randomization
either for myeloablative chemotherapy with stem cell
transplantation (melphalan, etoposide, carboplatin) or
four cycles of oral cyclophosphamide [14] (Figure 1).
Radiotherapy was administered for bone metastases and
non-progressing residual primary tumours in NB90. In
the NB97 trial, radiotherapy was reserved for patients
with residual MIBG-positive primary tumours only [15].
After initial treatment, all NB97 trial patients and a
l i m i t e dn u m b e ro fN B 9 0A S C Tp i l o tp a t i e n t sw e r e
scheduled for treatment with the monoclonal anti-GD2-
antibody ch14.18. This MAB was produced by BioInvent
International AB (Lund, Sweden), vialled by the pharma-
ceutical company Rentschler (Langheim, Germany), and
certified by the Paul-Ehrlich-Institute (Langen,
Germany) for investigational use within a national trial.
All hospitals collaborating in the German Neuroblas-
toma trials were qualified for antibody treatment when
their local ethics committee had approved the antibody
treatment. MAB ch14.18 was stored in two centres
(Tubingen and Cologne) and was made available to the
hospitals after induction chemotherapy documentation
of the individual patient was complete. The MAB
ch14.18 treatment regime consisted of an infusion of
20 mg/m²/d over 8-12 hours on five subsequent days.
This cycle was repeated every 2 months for a total of six
cycles. Concomitant intravenous morphine starting at a
dose of 1.0 mg/kg/d was strongly recommended for
pain control. In addition, other analgesic drugs (metami-
zol, paracetamol, tramadol) and cortisone could also be
administered.
The “as treated” outcome analysis was based on the
hypothesis that immunotherapy with MAB ch14.18 and
oral maintenance chemotherapy in the NB90 trial share
the concept of prolonged consolidation treatment of
potential minimal residual disease. Therefore, we com-
pared the survival data of the MAB ch14.18-treated
group with the group receiving oral maintenance che-
motherapy in the NB90 trial instead, as well as with
those patients who received no further consolidation
treatment after initial therapy. For this purpose, three
groups were defined: (1) antibody ch14.18 group con-
sisting of patients of trials NB90 and NB97 who received
MAB-ch14.18-antibody treatment but no oral mainte-
nance chemotherapy according to NB90; (2) oral NB90
maintenance chemotherapy group; (3) no consolidation
therapy after induction chemotherapy and ASCT or
induction chemotherapy only including all patients who
neither received MAB ch14.18 nor oral maintenance
chemotherapy according to NB90 trial.
Data were analyzed in May 2010 using the statistical
package SPSS version 17.0.0. Note, that all statistical
analyses are regarded as explorative, particularly all ana-
lyses of subgroups. Proportions were compared using
the two-tailed chi² test or Fisher’s exact test as appropri-
ate. Means were compared using the Mann Whitney
U-test. Survival curves were calculated according to
Kaplan-Meier. Survival times between two or more
groups were compared by the log-rank test. Event-free
survival time was calculated as the time from diagnosis
5 5 5 5 N5 N5 N6 N6 N5 N6
ASCT
N7 N7 N7 N7
AB AB AB AB AB AB NB97 1997-2002
& & & & N1 N1 N2 N2 N1 N2
ASCT
d1 d2
NB90 1990-1997
d1 d2 d1 d2 d1 d2 d1 d2 d1 d2
(1) MAB ch14.18 group
(2) NB90 maintenance group
(3) no consolidation group
N1 N2
Figure 1 Treatment scheme (for details of N1, N2, N5, N6, N7,
D1, and D2 see ‘Methods’ text, C = choice, R = randomization,
ASCT = myeloablative chemotherapy with autologous stem
cell transplant, AB = antibody ch14.18).
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Relapse, progression, death, and secondary malignant
disease were regarded as events. Overall survival time
was calculated as the time from diagnosis to death or
last examination if the patient survived. In the latter
case, the survival time was assigned as censored. Multi-
variable Cox regression was applied to analyze the prog-
nostic value of these risk factors with respect to event-
free and overall survival. The following potential six
explanatory prognostic factors were considered: (1) LDH
at diagnosis (abnormal vs. normal as reference), (2)
MYCN (amplified vs. not amplified as reference), (3) age
at diagnosis (continuous), (4) protocol (NB90 vs. NB97
as reference), (5) treatment group (antibody ch14.18
group as reference vs. NB90 oral maintenance che-
motherapy or no consolidation group), and (6) ASCT
(yes vs. no as reference). Models were build using a
stepwise variable selection procedure recommended by
Collett [16]. In the first step, all parameters were tested
one at a time in a univariate Cox regression. In the sec-
ond step, all parameters that appeared to be important
in step 1 were analyzed jointly by a Cox regression
backward selection. In a third step, all parameters that
were not important in step 1 were added, one at a time,
to the parameters which were important in step 2. After
the third step, the selection process due to Collett
ended since no additional risk factors were found. A p-
value of p≤ 0.05 in the score test served as the inclusion
criterion and a p-value of p>0.10 in the likelihood ratio
test served as the exclusion criterion.
Results
Patients’ characteristics
A total of 334 patients were included in this follow-up
study (see Table 1). The three treatment groups
(ch14.18, oral NB90 maintenance, and no consolidation
group) were not different in age, gender distribution,
MYCN status, and status prior to consolidation therapy.
By definition, ASCT was unbalanced between the
groups: The frequency of patients who underwent
ASCT prior to consolidation therapy was 62.0%, 0%, and
60.8% in the groups of ch14.18 treatment, oral NB90
maintenance chemotherapy, and no consolidation,
respectively. The median observation time was 11.11 years
(range: 2.27 - 18.57 years).
Consolidation treatment
A total of 164 patients received at least one antibody
cycle. The two remaining patients of the ch14.18 group
experienced relapse while waiting for the first cycle but
were included in the group according to the intention-
to-treat approach. Due to relapses, the number of
patients who received the next antibody cycles was
decreasing: A total of 148, 133, 107, 100, and 83 patients
received a 2
nd,3
rd,4
th,5
th, and 6
th ch14.18 cycle, respec-
tively. One patient had more than 6 antibody cycles.
MAB ch14.18 treatment was discontinued prematurely
in 6 children because their parents felt the side-effects
were unacceptable although the consulting physician
recommended continuation of MAB ch14.18 treatment.
Antibody treatment was stopped for medical reasons
because of capillary leak syndrome in 2 patients and
infectious hepatitis not related to antibody treatment in
1 patient. The median dose of MAB ch14.18 was
20 mg/m²/d (range: 12 to 40 mg/m²/d). Due to tolerance
during preparation, 2 patients had < 18 mg/m²/d (< 90%
of the scheduled dose). No patient had dose reduction
due to side-effects. Two patients received >22 mg/m²xd
(>110% of the scheduled dose). The median time interval
between antibody cycles or the preceding chemotherapy
to first antibody cycle was 65.5 days (range: 39.5 - 343
days; planned: 60 days). Detailed toxicity data have been
reported earlier [11]. The presence of allergic symptoms
such as rash, conjunctivitis, and pruritus during at least
one MAB ch14.18 cycle had no clear impact on the out-
come compared to no allergic symptoms (9-year EFS
44.2 ± 4.8% with symptoms of allergy vs. 35.0 ± 6.2%,
p = 0.105 and 9-year OS 50.0 ± 4.9% with allergy vs.
38.3 ± 6.5%, p = 0.080).
Outcome
The global 5-year-EFS rate was 39.5 ± 2.7% and the
5-year-OS rate was 48.4 ± 2.7%. Late events were rare
resulting in a very similar 9-year-EFS rate of 36.1 ± 2.6%
and a 9-year-OS rate of 40.1 ± 2.7%. Results of univari-
ate analysis comparing the three treatment groups are
found in Table 2. In the entire cohort, paired log-rank
test demonstrated a lower event rate after ch14.18 con-
solidation compared to no consolidation (p = 0.038) but
no clear difference between MAB ch14.18 treatment
and oral NB90 maintenance chemotherapy (p = 0.147,
Figure 2a). The overall survival rate was better after
antibody ch14.18 consolidation compared to no consoli-
dation therapy (p = 0.015) and to oral NB90 mainte-
nance chemotherapy (p = 0.023, Figure 2b). Extensive
subgroup analysis echoed the results of the global analy-
sis and demonstrated better overall survival after MAB
ch14.18 consolidation in patients without MYCN ampli-
fication, patients in CR/VGPR after induction, and
patients without residual bone marrow involvement
after induction. Moreover, 78 patients of trial NB97 who
underwent MAB ch14.18 consolidation after ASCT also
had a better OS rate compared to 99 patients who
underwent NB90 maintenance chemotherapy (p =
0.035). Accordingly, multivariable analysis found
better EFS and OS of MAB ch14.18 consolidation com-
pared to no consolidation therapy. In contrast, no out-
come difference was detected between MAB ch14.18
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according to NB90 (Table 3). The well-known risk fac-
tors, namely high LDH at diagnosis, MYCN amplifica-
tion, and higher age at diagnosis, were independently
associated with poor outcome; whereas, ASCT was
found to be the only factor to be associated with better
outcome.
Discussion
This follow-up analysis of the German neuroblastoma
trials demonstrated a possible benefit of antibody
ch14.18-based consolidation therapy compared to no
consolidation therapy on event-free and overall survival.
Of note is that a difference in event-free survival was not
found in a previous analysis performed in 2004 [11]. The
possible explanation is that antibody therapy can prevent
late relapses in patients with minimal residual disease.
Small patient series of consolidation therapy with sin-
gle agent chimeric MAB ch14.18 [7,8,10] or murine
MAB 3F8 [9] had shown encouraging results in high-
risk neuroblastoma patients. Combinations of antibodies
with cytokines [17,18], retinoic acid [19], or both [20]
were tested and found to be tolerable. The randomized
COG trial ANBL0032 was stopped after interim analysis
because the antibody-containing arm was more effective
than the retinoic acid standard arm [21]: Stage 4 neuro-
blastoma patients one year or older who received the
immunotherapy combination had a better outcome
(2-year EFS rate from randomization 63 ± 6%, 2-year
OS rate 84 ± 4%) compared to the standard arm with
retinoic acid (2-year EFS rate 42 ± 6%, p = 0.0155;
2-year OS rate 76 ± 5%, p = 0.1006). In order to com-
pare the results of our study to the ANBL0032 survival
rates, we have recalculated the survival times of our
patients from start of consolidation therapy. Patients of
the ch14.18 group had a 2-year EFS rate from the first
ch14.18 cycle of 50.0 ± 3.9% and a 2-year-OS rate of
70.1 ± 3.6%. The NB90 maintenance group achieved a
2-year EFS from first continuation chemotherapy cycle
of 46.5 ± 5.0% (p = 0.218) and a 2-year OS rate of 58.6
± 5.0% (p = 0.028). Many factors may explain the lower
survival rates in our study: (1) randomized design of
ANBL0032 vs. nonrandomized retrospective analysis in
NB90/97; (2) comparison of ch14.18-containing therapy
to retinoic acid in the ANBL0032 trial vs. metronomic
oral chemotherapy in NB90/97, and (3) combination of
ch14.18, retinoic acid, IL2, and GM-CSF vs. ch14.18
alone in NB90/NB97.
Further, data on anti-mouse antibodies are not avail-
able for both trials. One might expect that patients with
allergic reactions develop neutralizing antibodies result-
ing in inferior outcome. However, our data do not con-
firm such an effect. We found a trend for better
outcome of patients who developed allergic symptoms.
Table 1 Patients’ characteristics of the three treatment groups analyzed in this follow-up study
Treatment group Total p-value
Antibody18
ch14.18
Oral NB90 maintenance18
chemotherapy
No consolidation
No. of patients 166 99 69 334
Age at diagnosis median (years) 3.2 2.9 2.9 3.2 .262
range (years) 1.0-20.6 1.0-15.0 1.0-11.2 1.0-20.6
Sex male 95 54 43 192 .602
female 71 45 26 142
Protocol NB90 25 99 53 177 <.001
NB97 141 0 16 157
ASCT no 63 99 27 189 <.001
yes 103 0 42 145
MYCN status Normal 124 56 34 214 .358
Amplified 38 15 16 69
Not known 4 28 19 51
Disease status after initial treatment CR/VGPR 134 81 52 267 .567
PR 27 17 16 60
MR/SD 5 1 1 7
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Subgroup defined by Patient number Antibody ch14.18
group
Maintenance chemotherapy
group
No consolidation
group
Log-rank
p-value
All patients 344 5yEFS 45.2 ± 3.9% 34.1 ± 4.8% 33.3 ± 5.7% .098
5yOS 55.8 ± 3.9% 42.2 ± 5.0% 39.1 ± 5.9% .019
9yEFS 40.9 ± 3.8% 31.0 ± 4.7% 31.8 ± 5.6% .098
9yOS 45.8 ± 4.0% 33.9 ± 4.8% 34.6 ± 5.7% .019
With ASCT 145 5yEFS 50.5 ± 4.9% 38.1 ± 7.5% .241
5yOS 58.3 ± 4.9% 45.2 ± 7.7% .152
9yEFS 44.5 ± 4.9% 38.1 ± 7.5% .241
9yOS 47.0 ± 5.0% 40.5 ± 7.6% .152
No ASCT 189 5yEFS 36.5 ± 6.1% 34.1 ± 4.8% 25.9 ± 8.4% .133
5yOS 51.9 ± 6.3% 42.2 ± 5.0% 29.6 ± 8.8% .094
9yEFS 34.9 ± 6.0% 31.0 ± 4.7% 21.6 ± 8.1% .133
9yOS 43.9 ± 6.5% 33.9 ± 4.8% 25.4 ± 8.5% .094
NB90 177 5yEFS 48.0 ± 10% 34.1 ± 4.8% 37.7 ± 6.7% .300
5yOS 52.0 ± 10% 42.2 ± 5.0% 41.5 ± 6.8% .250
9yEFS 44.0 ± 9.9% 31.0 ± 4.7% 33.6 ± 6.5% .300
9yOS 48.0 ± 10.0% 33.9 ± 4.8% 37.6 ± 6.7% .250
NB97 157 5yEFS 44.7 ± 4.2% 18.8 ± 9.8% .067
5yOS 56.5 ± 4.2% 31.3 ± 11.6% .050
9yEFS 40.3 ± 4.1% 18.8 ± 9.8% .067
9yOS 45.3 ± 4.3% 23.4 ± 11.0% .050
NB90 maintenance
and NB97 ASCT
+ch14.18 patients
177 5yEFS 51.3 ± 5.7% 34.1 ± 4.8% .106
5yOS 60.3 ± 5.5% 42.2 ± 5.0% .035
9yEFS 44.7 ± 5.6% 31.0 ± 4.7% .106
9yOS 46.6 ± 5.7% 33.9 ± 4.8% .035
MYCN not amplified 214 5yEFS 48.4 ± 4.5% 37.0 ± 6.5% 35.3 ± 8.2% .166
5yOS 61.9 ± 4.4% 47.8 ± 6.5% 44.1 ± 8.5% .041
9yEFS 45.2 ± 4.5% 31.4 ± 6.3% 35.3 ± 8.2% .166
9yOS 52.0 ± 4.6% 34.9 ± 6.4% 38.0 ± 8.4% .041
MYCN amplified 69 5yEFS 34.2 ± 7.7% 20.0 ± 10.3% 31.3 ± 11.6% .997
5yOS 36.8 ± 7.8% 26.7 ± 11.4% 31.3 ± 11.6% .902
9yEFS 25.5 ± 7.2% 20.0 ± 10.3% 31.3 ± 11.6% .997
9yOS 24.9 ± 7.2% 20.0 ± 10.3% 31.3 ± 11.6% .902
CR/VGPR after
induction
267 5yEFS 47.0 ± 4.3% 34.4 ± 5.3% 36.5 ± 6.7% .185
5yOS 58.2 ± 4.3% 37.9 ± 5.4% 42.3 ± 6.9% .032
9yEFS 41.7 ± 4.3% 30.5 ± 5.2% 34.5 ± 6.6% .185
9yOS 45.8 ± 4.4% 32.8 ± 5.3% 36.3 ± 6.7% .032
CR after induction 166 5yEFS 54.9 ± 5.5 % 40.5 ± 7.1 % 48.6 ± 8.4 % .392
5yOS 62.2 ± 5.4 % 46.4 ± 7.2 % 57.1 ± 8.4 % .218
9yEFS 49.8 ± 5.5% 36.1 ± 6.9% 45.7 ± 8.4% .392
9yOS 51.6 ± 5.6% 37.8 ± 7.0% 48.6 ± 8.4% .218
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rospective nonrandomized design. However, patients were
treated in three different well defined groups and free choice
of continuation therapy was not possible. Except ASCT, all
other major risk factors were well balanced between the
three treatment groups (Table 1). The strength of this analy-
sis is that MAB ch14.18 has been used as a single agent.
Thus, the question arises as to exactly what MAB ch14.18
contributed to the beneficial effect of the immunotherapy
combination in the ANBL0032 trial.
Of note is that MAB ch14.18 was as effective as metro-
nomic 12 months oral maintenance chemotherapy of the
NB90 trial despite the fact that more than half of the
patients in the ch14.18 group, but none in the NB90
maintenance group, had undergone ASCT. It has been
shown in randomized trials that ASCT improves the out-
come of high risk neuroblastoma patients [3,14]. The mul-
tivariate analysis confirmed an independent impact of
both consolidation therapy and ASCT. Therefore, one
would actually expect an inferior outcome for NB90 main-
tenance patients without ASCT compared to the ch14.18
group including 61% ASCT patients which is not the case.
Conclusions
Our data clearly demonstrate that no consolidation ther-
apy is associated with worse outcome in high-risk neu-
roblastoma patients. Considering the result of this and
earlier [11] analysis, single agent ch14.18 consolidation
Table 2 Results of global and subgroup analysis (Continued)
PR after induction 60 5yEFS 37.0 ± 9.3% 29.4 ± 11.1% 25.0 ± 10.8% .644
5yOS 46.9 ± 9.8% 58.8 ± 11.9% 31.3 ± 11.6% .632
9yEFS 37.0 ± 9.3% 29.4 ± 11.1% 25.0 ± 10.8% .644
9yOS 46.9 ± 9.8% 35.3 ± 11.6% 31.3 ± 11.6% .632
No residual bone
marrow involvement
after induction
316 5yEFS 46.8 ± 4.0 % 36.0 ± 5.0 % 33.8 ± 5.7 % .122
5yOS 57.0 ± 4.0 % 43.4 ± 5.1 % 39.7 ± 5.9 % .033
9yEFS 42.1 ± 4.0% 32.6 ± 4.9% 32.2 ± 5.6% .122
9yOS 46.8 ± 4.1% 35.7 ± 5.0% 35.1 ± 5.8% .033
MAB ch14.18
NB 90 maintenance
No consolidation
MAB ch14.18
NB 90 maintenance
No consolidation
p=0.098 p=0.019
$%
Figure 2 Event-free survival (A) and overall survival (B) of 334 patients comparing ch14.18 consolidation (blue line), NB90 oral
maintenance therapy (green line), and no consolidation (red line).
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effective way of antibody based maintenance therapy
seems to be a combination immunotherapy with MAB
ch14.18, cytokines, and retinoic acid [21]. But these
results need confirmation by at least another rando-
mized trial. Further, metronomic low dose oral che-
motherapy consolidation was found as effective as MAB
ch14.18 consolidation in this retrospective analysis and,
therefore, also warrants further evaluation. Prospective
clinical trials must demonstrate if the concept of low
dose metronomic chemotherapy is feasible and effective
after ASCT and in combination with immunotherapy.
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